)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Bolt Biotherapeutics (BOLT) investor relations material
Bolt Biotherapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary14 Aug, 2025
Executive summary
Advanced BDC-4182 (claudin 18.2 ISAC) into Phase 1 for gastric/gastroesophageal cancer, with enrollment started in April 2025 and initial data expected in H1 2026.
BDC-3042 (dectin-2 agonist) completed Phase 1, showing promising results in lung cancer; seeking a partner for further development.
May 2024 restructuring prioritized pipeline, discontinued trastuzumab imbotolimod and BDC-1001, and reduced workforce by 50%.
Collaborations with Toray, Genmab, and Innovent continue to provide revenue and pipeline expansion opportunities.
Financial highlights
Collaboration revenue was $1.8M for Q2 2025 (up $0.5M YoY) and $3.0M for H1 2025 (down $3.5M YoY due to Innovent revenue recognition in 2024).
Net loss was $8.6M for Q2 2025 (improved from $21.2M YoY) and $19.6M for H1 2025 (improved from $32.0M YoY); net loss per share was $(4.46) for Q2 2025.
R&D expenses decreased to $7.5M in Q2 2025 (from $15.4M YoY), mainly due to program discontinuation and lower salaries.
G&A expenses were $3.5M in Q2 2025 (down from $4.9M YoY) and $7.3M in H1 2025 (down from $10.7M YoY).
Cash, cash equivalents, and marketable securities totaled $48.5M as of June 30, 2025.
Outlook and guidance
Cash and equivalents expected to fund operations through mid-2026, but substantial doubt exists about ability to continue as a going concern without additional capital.
Initial data from BDC-4182 Phase 1 anticipated in H1 2026; expansion to additional countries planned in H2 2025.
Ongoing efforts to secure partnerships or raise capital; future funding needs will grow with clinical advancement.
Elaborate on the status of Genmab and Toray collaborations.
Explain the reasons for decreased R&D expenses.
Assess the impact of the reverse stock split.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Bolt Biotherapeutics earnings date
Q3 202514 Nov, 2025
Next Bolt Biotherapeutics earnings date
Q3 202514 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Bolt Biotherapeutics Inc. is a clinical-stage biotechnology company engaged in developing innovative immunotherapies for cancer treatment. The company's proprietary technology, Boltbody Immune-stimulating Antibody Conjugate, represents a novel approach in immuno-oncology, aiming to transform "cold" tumors into "hot" tumors by engaging and activating myeloid cells to directly attack tumor cells. Bolt Biotherapeutics is advancing its lead clinical candidate, BDC-1001, a HER2-targeting Boltbody ISAC for the treatment of patients with HER2-positive solid tumors. Additionally, the company is developing BDC-3042, a myeloid modulating agonistic antibody aimed at reprogramming tumor-associated macrophages to enhance anti-tumor immunity, with plans to enter clinical trials. The company is headquartered in Redwood City, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage